Skip to main content

Table 2 1-year, 3-year, 5-year survival rate in four cohorts

From: Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database

Items

Survival time

Survival rate

Mean survival time [95% CI] (months)

1-year survival (95% CI)

3-year survival (95% CI)

5-year survival (95% CI)

Primary hepatic neuroendocrine tumors (PH-NETs):

30.64 (24.75–36.53)

56.43 (48.15–64.36)

30.00 (23.03–38.04)

18.57 (13.00–25.82)

Hepatocellular carcinoma (HCC in situ):

25.11 (20.20–30.02)

55.00 (46.74–63.00)

21.43 (15.44–28.94)

10.71 (6.60–16.93)

Gastrointestinal neuroendocrine tumors in situ (GI-NETs in situ):

41.62 (35.32–47.92)

74.29 (66.47–80.81)

42.86 (34.96–51.14)

27.86 (21.10–35.80)

Gastrointestinal neuroendocrine tumors with liver metastasis (GI-NETs-LM):

24.81 (21.15–36.60)

64.75 (56.51–72.20)

30.94 (23.85–39.05)

8. 63 (5.01–14.48)